Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998775 · ClinicalTrials.gov registry record · Early Phase 1
Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding
A Early Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 54
- Enrollment target
NCT02998775 is a Early Phase 1 study that has completed, run by Eisai. The registered enrollment target is 54 participants.
The verdict
NCT02998775, a Early Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. The primary objective of the study is to obtain plasma from participants for use in in vitro protein binding studies.
Interventions
- DRUG Plasma Sampling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-12-02 |
| Est. Completion | 2017-07-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998775
The ClinicalTrials.gov registry entry for NCT02998775 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plasma Sampling is the first listed.
NCT02998775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02998775 about?
NCT02998775 is a clinical study titled "Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding". E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. The primary objective of the study is to obtain plasma from participants for use in in vitro protein bi...
What is the current status of trial NCT02998775?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 54 participants. The study started on 2016-12-02. Estimated completion is 2017-07-08.
What interventions are being tested in trial NCT02998775?
The interventions under investigation include: Plasma Sampling (DRUG).
Who is sponsoring clinical trial NCT02998775?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.